Phase 1/2 Study of DSP-7888 in Patients With Myelodysplastic Syndrome (MDS)

Trial Profile

Phase 1/2 Study of DSP-7888 in Patients With Myelodysplastic Syndrome (MDS)

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 07 Mar 2017

At a glance

  • Drugs Adegramotide/nelatimotide (Primary)
  • Indications Myelodysplastic syndromes
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Sumitomo Dainippon Pharma
  • Most Recent Events

    • 01 Mar 2017 Planned primary completion date changed from 1 Jun 2017 to 1 Dec 2017.
    • 06 Dec 2016 Preliminary results (n=12; Data cut off May 25th 2016) from a Phase 1/2 Study of DSP-7888, presented at the 58th Annual Meeting and Exposition of the American Society of Hematology
    • 06 Dec 2016 Preliminary results published in a Boston Biomedical media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top